ABSTRACT
The antiandrogenic therapy (ADT) for prostate cancer represents an additional risk factor for the development of osteoporosis and fragility fractures. Still, bone health of patients on ADT is often not evaluated. After literature research we found that simple preventive measures can prevent bone loss in these patients, resulting in more cost-effective solutions to the public health system and family when compared to the treatment of fractures.
A terapia antiandrogênica (TAD) para câncer de próstata representa um fator de risco adicional para o desenvolvimento de osteoporose e fraturas de fragilidade. Mesmo assim, a saúde óssea dos pacientes sob TAD frequentemente não é avaliada. Após pesquisa na literatura, observamos que medidas preventivas simples podem prevenir a perda de massa óssea nestes pacientes, resultando em soluções mais custo-efetivas para o Sistema Público de Saúde e familiares quando comparadas ao tratamento das fraturas.
Subject(s)
Humans , Gonadotropin-Releasing Hormone , Hormones , Osteoporosis , Prostatic Neoplasms , TestosteroneABSTRACT
combined with LNG-IUS) and control group ( n =36, treated by only LNG-IUS).After treatment were compared the improvement of uterine volume , dysmenorrhea and menorrhagia and other symptoms in the two groups. [Results] After treatment, the uterine volume, dysmenorrhea severity score and menstrual flow in observation group were significantly lower than those in control group ( P<0.05);during follow-up time, there occurred 7 cases(20.58%) of dripping vaginal bleeding and 4 cases(11.76%) of decyclization in control group , while in observation group there was none of occurrence . [ Conclusion ] GnRHa combined with LNG-IUS is of better clinical efficacy in the treatment of adenomyosis than LNG-IUS used alone.
ABSTRACT
Autoimmune progesterone dermatitis is a rare autoimmune response to endogenous progesterone that usually occurs in fertile females. Cutaneous or mucosal lesions develop cyclically during the luteal phase of the menstrual cycle when progesterone levels are elevated. Symptoms usually start 3-10 days before menstruation and resolve 1-2 days after menstruation ceases. We report the case of a 48-year-old woman with intermittent eczematous skin lesions of the legs, forearms, and buttocks. She was diagnosed with allergic contact dermatitis, and topical steroids were prescribed. Her skin eruptions waxed and waned for 6 years and were associated with her menstrual cycle. We performed an intradermal test using progesterone, which was positive, and prescribed gonadotropin-releasing hormone analogues monthly for 3 months. The patient's skin lesions improved, confirming the diagnosis. Autoimmune progesterone dermatitis should be included in the differential diagnosis of recurrent eczema that is refractory to treatment in women of child-bearing age.
Subject(s)
Female , Humans , Middle Aged , Autoimmune Diseases , Autoimmunity , Buttocks , Dermatitis , Dermatitis, Allergic Contact , Diagnosis, Differential , Eczema , Forearm , Gonadotropin-Releasing Hormone , Intradermal Tests , Leg , Luteal Phase , Menstrual Cycle , Menstruation , Progesterone , Skin , SteroidsABSTRACT
Since recent years, the incidence of precocious puberty has been rising. However, questions regarding its treatment and other conditions remain. This article reviews recent published papers with long-term outcome data and guidelines, and systemical introduction to identification of precocious puberty, different treatment options, therapeutic goals, and indications for different types of diseases, as well as adverse effects of drugs.
ABSTRACT
Ovarian cancer is sex hormone-dependent. Gonadotropin releasing hormone (GnRH) analogues inhibit ovarian cancer not only through the hypothalamus-pituitary-gonadal axis, but also through directly inhibiting the proliferation and inducing the apoptosis via GnRH receptors on the ovarian carcinoma cells. In addition, GnRH analogues target GnRH receptors on the cancer cells and can serve as a carrier for cytotoxic agents, improving the efficiency of cytotoxic agents and lowering the side effect. In a word, treatment with GnRH analogues may be a valuable alternative for advanced and recurrent ovarian cancer.
ABSTRACT
The effect of gonadotropin-releasing hormone analogue(GnRHa) on lineafity growth and final height in 82 girls with central precocious puberty (CPP) was evaluated. The growth velocity in the second year was positively correlated with the difference value of bone age between the first year and the second year after treatment. The height standard deviation score for bone age and predicted aduh height increased after treatment. Twenty-six girls who had been followed to final height obtained better adult height than target height. GnRHa in combination with aerobic exercise increases linear growth and final height in girls with CPP.
ABSTRACT
Objective To observe the clinical effect of gonadotropin releasing hormone analogues in treatment of the girls with idiopathic central precocious puberty(ICPP). Methods Twelve girls with ICPP received therapy with GnRH-A.Before and after the end of treatment for 6 months,secondary sexual characteristics and growth velocity were observed,pelvic ultrasonic examination,X-ray bone age(BA),serum level of E_2 and LHRH stimulating test were detected,and the predicted adult height(PAH) was analysed. Results After treatment,the size of breasts,uterus and ovaries were significantly reduced.The basic and peak levels of serum LH and FSH by LHRH stimulation were also significantly reduced.The ratio of BA/CA(chronology age)was decreased.The PAH was increased. Conclusions GnRH-A can effectively depress the sexual characteristics,reduce the maturation of BA,and also improve the PAH in girls with ICPP.
ABSTRACT
Ovarian cancer is sex hormone-Dependent.Gonadotropin releasing hormone (GnRH) analogues inhibit ovarian cancer not only through the hypothalamus-pituitary-gonadal axis, but also through directly inhibiting the proliferation and inducing the apoptosis via GnRH receptors on the ovarian carcinoma cells.In addition, GnRH analogues target GnRH receptors on the cancer cells and can serve as a carrier for cytotoxic agents, improving the efficiency of cytotoxic agents and lowering the side effect.In a word, treatment with GnRH analogues may be a valuable alternative for advanced and recurrent ovarian cancer.